GSK sees earnings rise amid good demand for vaccines


Pharmaceutical company GlaxoSmithKline says its net profit rose 50 percent in the third quarter to 808 million pounds thanks in part to strong sales of its vaccine products. CEO Andrew Witty cited "the sustained progress we have made over the course of 2016 to deliver sales growth of new products, maintain effective cost control and execute on our restructuring and integration plans."



from Biotech News